When combined with PD-L1 blockade, IDO nano-inhibitor enhanced the anti-tumor efficacy of anti-PD-L1 via decreasing the proportion of immune suppressive cells (Tregs) and increasing the proportion of immune effector cells (IFN-γ secreting tumor-infiltrating T cells) 153. The gene discussed is CD274; the disease is neoplasm.